Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Stromedix General Information
Stromedix developed innovative therapies targeting fibrosis and organ failure. Its lead compound, STX‑100, completed Phase 1 clinical trials with plans for Phase 2 in idiopathic pulmonary fibrosis and chronic allograft nephropathy. The FDA granted orphan drug designation to STX‑100 for both indications. The company was acquired by Biogen Idec in February 2012.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
United States
United States
Drug Pipeline
STX-100
Phase 2Key Partnerships
University of California San Francisco (UCSF) licensing agreement for pipeline expansion, investors included Atlas Venture, New Leaf Venture Partners, Frazier Healthcare Ventures, Bessemer Venture Partners, Red Abbey Venture Partners, Biogen Idec was also an investor before acquiring the company
Stromedix Funding
No funding data available
To view Stromedix's complete valuation and funding history, request access »